PT  - JOURNAL ARTICLE
AU  - Li, Maggie
AU  - Beck, Evan J.
AU  - Laeyendecker, Oliver
AU  - Eby, Yolanda
AU  - Tobian, Aaron AR
AU  - Caturegli, Patrizio
AU  - Wouters, Camille
AU  - Chiklis, Gregory R.
AU  - Block, William
AU  - McKie, Robert
AU  - Joyner, Michael
AU  - Wiltshire, Timothy D.
AU  - Dietz, Allan B.
AU  - Gniadek, Thomas J.
AU  - Shapiro, Arell
AU  - Yarava, Anusha
AU  - Lane, Karen
AU  - Hanley, Daniel
AU  - Bloch, Evan M.
AU  - Shoham, Shmuel
AU  - Cachay, Edward R.
AU  - Meisenberg, Barry R.
AU  - Huaman, Moises A.
AU  - Fukuta, Yuriko
AU  - Patel, Bela
AU  - Heath, Sonya L.
AU  - Levine, Adam C.
AU  - Paxton, James H.
AU  - Anjan, Shweta
AU  - Gerber, Jonathan M.
AU  - Gebo, Kelly A.
AU  - Casadevall, Arturo
AU  - Pekosz, Andrew
AU  - Sullivan, David J.
AU  - ,
TI  - High Viral Specific Antibody Convalescent Plasma Effectively Neutralizes SARS-CoV-2 Variants of Concern
AID  - 10.1101/2022.03.01.22271662
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.01.22271662
4099  - http://medrxiv.org/content/early/2022/03/02/2022.03.01.22271662.short
4100  - http://medrxiv.org/content/early/2022/03/02/2022.03.01.22271662.full
AB  - The ongoing evolution of SARS-Co-V2 variants to omicron severely limits available effective monoclonal antibody therapies. Effective drugs are also supply limited. Covid-19 convalescent plasma (CCP) qualified for high antibody levels effectively reduces immunocompetent outpatient hospitalization. The FDA currently allows outpatient CCP for the immunosuppressed. Viral specific antibody levels in CCP can range ten-to hundred-fold between donors unlike the uniform viral specific monoclonal antibody dosing. Limited data are available on the efficacy of polyclonal CCP to neutralize variants. We examined 108 pre-delta/pre-omicron donor units obtained before March 2021, 20 post-delta COVID-19/post-vaccination units and one pre-delta/pre-omicron hyperimmunoglobulin preparation for variant specific virus (vaccine-related isolate (WA-1), delta and omicron) neutralization correlated to Euroimmun S1 IgG antibody levels. We observed a 2-to 4-fold and 20-to 40-fold drop in virus neutralization from SARS-CoV-2 WA-1 to delta or omicron, respectively. CCP antibody levels in the upper 10% of the 108 donations as well as 100% of the post-delta COVID-19/post-vaccination units and the hyperimmunoglobulin effectively neutralized all three variants. High-titer CCP neutralizes SARS-CoV-2 variants despite no previous donor exposure to the variants.Key points All of the post-delta COVID-19/post vaccination convalescent plasma effectively neutralizes the omicron and delta variants.High-titer CCP and hyperimmunoglobulin neutralizes SARS-CoV-2 variants despite no previous donor exposure to the variants.Competing Interest StatementTG- paid consultant for Fresenius Kabi; GC and RM are on the Board of Innovative Transfusion Medicine; WB-Board of Blood Centers of America; AC- Scientific Advisory Board of Sabtherapeutics (cow-derived human immunoglobulins COVID-19 treatment and other infectious diseases) and Ortho Diagnostics Speakers Bureau; EB- member of the FDA Blood Products Advisory Committee. All other authors report no relevant disclosures.Funding StatementThe study was funded principally by the U.S.Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency (DHA) (contract number: W911QY2090012), with additional support from Bloomberg Philanthropies, State of Maryland, the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) 3R01AI152078-01S1, NIH NIAID contract N7593021C00045 to the Johns Hopkins Center of Excellence in Influenza Research and Response (JH CEIRR), NIH National Center for Advancing Translational Sciences U24TR001609 and UL1TR003098, Division of Intramural Research NIAID NIH, Mental Wellness Foundation, Moriah Fund, Octapharma, HealthNetwork Foundation and the Shear Family Foundation. The study sponsors did not contribute to the study design, the collection, analysis, and interpretation of data, and the decision to submit the paper for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approvals were obtained from the Institutional Review Boards at Johns Hopkins University School of Medicine as single IRB for all participating sites and the Department of Defense (DoD) Human Research Protection Office. All participants provided written informed consent. The post-delta COVID-19/post-vaccination plasma aliquots were obtained from Innovative Transfusion Medicine after research informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors